A. 1) On September 29, 2008, the Plaintiff entered into an insurance contract with B as the insured on September 29, 2008, and as the Defendant’s non-payment of dividends, the Defendant’s “CI insurance” (hereinafter “instant insurance”).

(2) According to the instant insurance contract, the Defendant shall pay 80 million won of the basic insurance amount (100 million won) to the Plaintiff, the beneficiary, in accordance with the State contract (the KF Insurance Money) where the insured was diagnosed and confirmed as a “serious disease.” In the event that the insured was diagnosed and confirmed as a “satisfic species,” the Plaintiff shall be paid KRW 6 million according to the CI additional security agreement.

B. Contents 1) According to the main terms and conditions of the general insurance agreement and the special agreement to guarantee non-distribution CI additional terms and conditions incorporated into the insurance contract of this case, the term “serious diseases” includes significant cancer. “Serious cancer” refers to malicious species, where a malicious cell exists and its surrounding organization can be characterized by sediment and destructive proliferation of malicious cells (Provided, That this is excluded from dynamic disease, spathy, spathy, and spathic spathic spathic spathic spathic spathic spathic spathics).

The term "finite species" means diseases specified in the Korean Standard Disease Classification (Korean Standard Disease Disease Classification) or the U.S. S. S. S. S. S. S. S. S. S. S. S. S.

3) 그리고 암 또는 경계성 종양의 진단 확정은 해부병리 전문의사 또는 임상병리 전문의사 자격증을 가진 자에 의하여 내려져야 하며, 이 진단은 조직(fixed tissue)검사, 미세침흡인검사(fine needle aspiration biospy) 또는 혈액(hemic system)검사에 대한 현미경 소견을 기초로 하여야 한다. 다. 피보험자 B에 대한 진단 등의 경과 1) B은 2013. 6. 7. C병원에 직장의 점막하 병변으로 내원하여 2013. 6. 7. 대장 내시경적 절제시술을 받았다.

The results of pathology inspection conducted on June 13, 2013, where D in 2 Syriology D reads the species synad in B.